Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Fatigue is a common symptom in primary biliary cirrhosis (PBC). In animal models of cholestasis, abnormalities in serotonin neurotransmission are observed with fatigue. The role of selective serotonin reuptake inhibitors in fatigue-related PBC, however, is unknown. A double-blind, placebo-controlled study design was conducted to determine the safety and efficacy of fluoxetine for the treatment of fatigue in PBC. Patients were randomized to fluoxetine, 20 mg daily, or matched placebo for 8 weeks' duration. Fatigue was assessed by the Fisk Fatigue Impact Scale (FFIS). The primary study endpoint was a > or =50% reduction in overall FFIS score at the end of treatment. Health-related quality of life (HRQL) was assessed as a secondary endpoint. Among 220 consecutively screened patients, only 18 (9%) eligible individuals were randomized to fluoxetine (n=10) or placebo (n=8) for 8 weeks. Baseline variables including median FFIS scores (52 vs 42; P=0.21) were similar between treatment arms (P > 0.05). After 8 weeks of therapy, no statistically significant change in median FFIS score was observed in the fluoxetine group. Median FFIS score in the placebo group was reduced (42 to 28), but not statistically significant. No difference in HRQL was observed between treatment arms after 8 weeks. Fourteen (78%) patients completed therapy, while four (22%) individuals withdrew from the trial. Three of the four patients had drug-related adverse events with fluoxetine. In this study, fluoxetine did not improve fatigue in PBC and was associated with adverse events.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Altered serotonin neurotransmission may mediate fatigue in chronic liver disease (183) ; however, ondansetron, an antagonist to serotonin receptor, did not relieve fatigue in a clinical trial.(184)”
From Primary Biliary Cholangitis: 2018 Practice Guidance from the American Association for the Study of Liver Diseases (2019) · cites this paper as [184]
Citations
Cites
The CES-D Scale: A Self-Report Depression Scale for Research in the General Population
Radloff, L. S. (1977) · Applied Psychological Measurement · doi:10.1177/014662167700100306 · Cited by 53,267 · cited 7×
“%) individuals were not randomized based on scores ≥16 points on the CES-D questionnaire.”
MethodInfluentialMeasuring the Functional Impact of Fatigue: Initial Validation of the Fatigue Impact Scale
Fisk, J. D., Ritvo, P. G., Ross, L., Haase, D. A., Marrie, T. J., & Schlech, W. F. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.supplement_1.s79 · Cited by 1,541 · cited 1×
“Baseline fatigue severity was determined in all randomized patients with the Fisk Fatigue Impact Scale (FFIS) [22].”
MethodDEMITRACK, M. A., DALE, J. K., STRAUS, S. E., LAUE, L., LISTWAK, S. J., KRUESI, M. J. P., CHROUSOS, G. P., & GOLD, P. W. (1991) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-73-6-1224 · Cited by 727 · cited 1×
“The recognition of defective central serotonin neural activity is also observed with nonhepatic disorders such as chronic fatigue syndrome [27].”
BackgroundYounossi, Z. M., Guyatt, G., Kiwi, M., Boparai, N., & King, D. (1999) · Gut · doi:10.1136/gut.45.2.295 · Cited by 670 · cited 9×
“Springer Health-related quality-of-life assessment was performed with the Chronic Liver Disease Questionnaire (CLDQ) [23].”
MethodInfluentialThe presentation and diagnosis of 100 patients with primary biliary cirrhosis
Sherlock, S., & Scheuer, P. J. (1973) · New England Journal of Medicine · doi:10.1056/nejm197309272891306 · Cited by 504 · cited 1×
“Bile duct injury from portal and periportal inflammation often results in progressive fibrosis and eventual cirrhosis [1].”
BackgroundUrsodiol for the Long-Term Treatment of Primary Biliary Cirrhosis
Poupon, R. E., Poupon, R., & Balkau, B. (1994) · New England Journal of Medicine · doi:10.1056/nejm199405123301903 · Cited by 497
Ursodeoxycholic acid in the treatment of primary biliary cirrhosis
Lindor, K. D., Dickson, E. R., Baldus, W. P., Jorgensen, R. A., Ludwig, J., Murtaugh, P. A., Harrison, J. M., Wiesner, R. H., Anderson, M. L., Lange, S. M., et al. (1994) · Gastroenterology · doi:10.1016/0016-5085(94)90021-3 · Cited by 487
Self-citationSWAIN, M. G. (2000) · Clinical Science · doi:10.1042/cs0990001 · Cited by 383 · cited 1×
“Both serotonergic and noradrenaline pathways have been implicated [26].”
BackgroundPrince, M., Chetwynd, A., Newman, W., Metcalf, J. V., & James, O. F. W. (2002) · Gastroenterology · doi:10.1053/gast.2002.36027 · Cited by 348
Christensen, E., Crowe, J., Doniach, D., Popper, H., Ranek, L., Rodés, J., Tygstrup, N., & Williams, R. (1980) · Gastroenterology · doi:10.1016/0016-5085(80)90571-5 · Cited by 273
Cited by
Lindor, K. D., Gershwin, E. M., Poupon, R., Kaplan, M., Bergasa, N. V., & Heathcote, J. E. (2009) · Hepatology · doi:10.1002/hep.22906 · Cited by 1,099
Self-citationLindor, K. D., Bowlus, C. L., Boyer, J., Levy, C., & Mayo, M. (2019) · Hepatology · doi:10.1002/hep.30145 · Cited by 913
“(184) Fluoxetine, a selective serotonin reuptake inhibitor, also did not improve fatigue.(185) Patients with PBC-related fatigue have excessive daytime sleepiness.”
BackgroundSelf-citationCarey, E. J., Ali, A. H., & Lindor, K. D. (2015) · The Lancet · doi:10.1016/s0140-6736(15)00154-3 · Cited by 735
Self-citationHohenester, S., Oude-Elferink, R. P. J., & Beuers, U. (2009) · Seminars in Immunopathology · doi:10.1007/s00281-009-0164-5 · Cited by 179
“The selective serotonin reuptake inhibitors fluvoxamine and fluoxetine also failed to exert beneficial effects on fatigue in this patient group [311, 312].”
BackgroundPrimary biliary cholangitis: Epidemiology, prognosis, and treatment
Trivella, J., John, B. V., & Levy, C. (2023) · Hepatology Communications · doi:10.1097/hc9.0000000000000179 · Cited by 159
Metadata
- Authors
- Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D.
- Affiliations
- Mayo Clinic (US)
- Corresponding author
- Talwalkar, Jayant A.
- ORCID
- Lindor, Keith D.
- Venue
- Digestive Diseases and Sciences
- Published
- 2006-10-20
- Volume
- 51
- Issue
- 11
- Pages
- 1985-1991
- ISSN
- 0163-2116 (ISSN-L)
- 1573-2568
- OpenAlex
- W2024885291
- Cited by
- 54
- References
- 35
- Citations by year
- 2026: 2 · 2025: 5 · 2024: 2 · 2023: 3 · 2022: 4 · 2020: 2 · 2019: 4 · 2018: 4 · 2017: 1 · 2016: 4 · 2015: 2 · 2014: 3 · 2013: 1 · 2012: 2
- FWCI
- 2.72
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Digestive Diseases and Sciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
- Health Sciences › Medicine › Psychiatry and Mental health › Fibromyalgia and Chronic Fatigue Syndrome Research
- Health Sciences › Medicine › Surgery › Pediatric Hepatobiliary Diseases and Treatments
- Keywords
- fluoxetine, primary biliary cirrhosis, fatigue, selective serotonin reuptake inhibitors, serotonergic neurotransmission, cholestasis, health-related quality of life, drug adverse events
- MeSH terms
- Adolescent, Adult, Aged, Double-Blind Method, Fatigue, Fluoxetine, Humans, Liver Cirrhosis, Biliary, Middle Aged, Prospective Studies, Quality of Life, Treatment Outcome, Selective Serotonin Reuptake Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial. https://app.cochat.ai/papers/10.1007/s10620-006-9397-5
- The paper
- Talwalkar, J. A., Donlinger, J. J., Gossard, A. A., Keach, J. C., Jorgensen, R. A., Petz, J. C., & Lindor, K. D. (2006). Fluoxetine for the treatment of fatigue in primary biliary cirrhosis: a randomized, double‐blind controlled trial. Digestive Diseases and Sciences. https://doi.org/10.1007/s10620-006-9397-5
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.